Incyte To Present New Data From Dermatology Portfolio At EADV 2025 Congress

+2.05%

Incyte Corporation

INCY

102.52

+2.05%

- 24-week data from the Phase 3 STOP-HS clinical trial program of povorcitinib in patients with hidradenitis suppurativa (HS) selected as a late-breaking oral presentation

Today Incyte (NASDAQ:INCY) announced that it will present new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress, held from September 17 – 20, in Paris. Highlights include late-breaking, oral and poster presentations featuring data for povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, and ruxolitinib cream (Opzelura®), a topical JAK1/2 inhibitor.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.